公开(公告)号：US20070032666A1

公开(公告)日：2007-02-08

申请号：US11414552

申请日：2006-05-01

Applicant: Roger Read ,  Naresh Kumar

Inventor： Roger Read ,  Naresh Kumar

IPC: C07D305/12

CPC classification number: C08F20/00 ,  A01N43/08 ,  C07D307/58 ,  C08F24/00

Abstract: The present invention relates to the side chain functionalization of fimbrolides (halogenated 3-alkyl-5-methylene-2(5H)-furanones) and their synthetic analogues, that yields fimbrolides substituted with a halogen, an oxygen or a nitrogen functionality in the alkyl chain, especially fimbrolide alcohols, caboxylate and sulfinate and sulfonate esters, ethers, aldehydes, ketones, acids, amides, nitro derivatives, hydrophobic, hydrophilic and fluorophilic alkyl derivatives and polymers.

Abstract translation: 本发明涉及福滨洛尔（卤代3-烷基-5-亚甲基-2（5H） - 呋喃酮）及其合成类似物的侧链官能化，其产生在烷基中被卤素，氧或氮官能团取代的菲莫拉林 链，特别是曲芬洛尔醇，卡波西铵和亚磺酸盐和磺酸酯，醚，醛，酮，酸，酰胺，硝基衍生物，疏水性，亲水和氟烷基衍生物和聚合物。

公开(公告)号：US20070010568A1

公开(公告)日：2007-01-11

申请号：US10544520

申请日：2003-02-07

Applicant: Anita Mehta ,  Bruhaspathy Miriyala ,  Naresh Kumar ,  Jang Gupta

Inventor： Anita Mehta ,  Bruhaspathy Miriyala ,  Naresh Kumar ,  Jang Gupta

IPC: A61K31/403 ,  C07D209/02

CPC classification number: C07D471/08

Abstract: This invention relates to derivatives of substituted azabicyclo hexanes. The compound of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for the preparation of compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.

Abstract translation: 本发明涉及取代的氮杂双环己烷的衍生物。 本发明化合物可用作毒蕈碱受体拮抗剂，可用于治疗通过毒蕈碱受体介导的呼吸道，尿路和胃肠道系统的各种疾病。 本发明还涉及制备本发明化合物的方法，含有本发明化合物的药物组合物以及通过毒蕈碱受体介导的疾病的治疗方法。

公开(公告)号：US20060247225A1

公开(公告)日：2006-11-02

申请号：US10543585

申请日：2003-01-23

Applicant: Anita Mehta ,  Arundutt Silamkoti ,  Naresh Kumar ,  Jang Gupta

Inventor： Anita Mehta ,  Arundutt Silamkoti ,  Naresh Kumar ,  Jang Gupta

IPC: A61K31/55 ,  A61K31/46

CPC classification number: C07D401/04 ,  C07D209/52 ,  C07D401/06 ,  C07D403/04 ,  C07D405/04 ,  C07D405/06 ,  C07D409/04

Abstract: This invention generally relates to derivatives of 3,6 disubstituted azabicyclo hexanes. The compounds of this invention can function as muscarinic receptor antagonists and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.

公开(公告)号：US20060106220A1

公开(公告)日：2006-05-18

申请号：US11300976

申请日：2005-12-14

Applicant: Andrew Heaton ,  Naresh Kumar ,  Graham Kelly ,  Alan Husband

Inventor： Andrew Heaton ,  Naresh Kumar ,  Graham Kelly ,  Alan Husband

IPC: A61K31/4745 ,  C07D471/04 ,  C07D405/02 ,  C07D409/02 ,  C07D401/02 ,  A61K31/4709

CPC classification number: C07D311/26 ,  A23L33/10 ,  A23L33/11 ,  A23V2002/00 ,  C07D311/36 ,  C07D311/38 ,  C07D311/58 ,  C07D471/06 ,  A23V2250/2116 ,  A23V2200/30

Abstract: Isoflavone compounds and analogues thereof, compositions containing same and therapeutic methods of treatment involving same are described.

Abstract translation: 描述异黄酮化合物及其类似物，含有其的组合物和涉及其的治疗方法。

公开(公告)号：US20050215772A1

公开(公告)日：2005-09-29

申请号：US10525231

申请日：2003-08-19

Applicant: Naresh Kumar

Inventor： Naresh Kumar

IPC: A01N43/08 ,  A01N43/36 ,  A61L2/16 ,  A61L12/14 ,  A61P17/10 ,  A61P31/00 ,  A61P33/00 ,  C07D207/38 ,  C07D207/44 ,  C07D307/34 ,  C07D307/60 ,  C07D307/66 ,  C07H19/22 ,  C07D207/24 ,  C07H19/048

CPC classification number: C07D207/44 ,  A01N43/08 ,  A01N43/36 ,  A61L2/16 ,  A61L12/14 ,  C07D207/38 ,  C07D307/34 ,  C07D307/60 ,  C07D307/66

Abstract: Novel synthesis methods, to the products of such novel methods, and to uses of these products. In particular, the present invention provides methods for the reactions of furanones, in particular fimbrolides, with amines. The invention has particular application in the synthesis of halogenated 1,5-dihydro-pyrrol-2-one, 5-halomethylene substituted 1,5-dihydropyrrol-2-ones (lactam analogues of fimbriolides), 5-amino substituted furanones and 5-aminomethylene-2(5H)-furanones and their synthetic analogues. The invention also relates to novel compounds and uses thereof.

Abstract translation: 新型合成方法，对这些新方法的产品，以及这些产品的用途。 特别地，本发明提供了呋喃酮，特别是福滨洛尔与胺反应的方法。 本发明特别适用于卤代1,5-二氢 - 吡咯-2-酮，5-卤代亚甲基取代的1,5-二氢吡咯-2-酮（呋喃草醚的内酰胺类似物），5-氨基取代的呋喃酮和5- 氨基亚甲基-2（5H） - 呋喃酮及其合成类似物。 本发明还涉及新化合物及其用途。

公开(公告)号：US06900296B2

公开(公告)日：2005-05-31

申请号：US10276505

申请日：2001-05-07

Applicant: Mohammad Salman ,  Parma Chandra Ray ,  Kiran Kumar Gangakhedkar ,  Harish Niranjan Lal Dorwal ,  Naresh Kumar

Inventor： Mohammad Salman ,  Parma Chandra Ray ,  Kiran Kumar Gangakhedkar ,  Harish Niranjan Lal Dorwal ,  Naresh Kumar

IPC: C07H17/08 ,  C07H1/00

CPC classification number: C07H17/08

Abstract: The invention relates to a cost effective and industrially advantageous process for the selective methylation of a hydroxy group at the 6 position of erythromycin A derivative which comprised methylating the erythromycin A derivative with a methylating agent in a mixture of toluene and a ploar aprotic solvent.

Abstract translation: 本发明涉及在红霉素A衍生物的6位选择性甲基化羟基的成本有效和工业上有利的方法，该方法包括用甲基化剂甲苯化红霉素A衍生物与甲苯和异质非质子溶剂的混合物。

公开(公告)号：US5756729A

公开(公告)日：1998-05-26

申请号：US728808

申请日：1996-10-09

Applicant: Jag Mohan Khanna ,  Naresh Kumar ,  Chandrahas Khanduri ,  Mukesh Kumar Sharma ,  Pankaj Sharma ,  Swargam Sathyanarayan ,  Girij Pal Singh

Inventor： Jag Mohan Khanna ,  Naresh Kumar ,  Chandrahas Khanduri ,  Mukesh Kumar Sharma ,  Pankaj Sharma ,  Swargam Sathyanarayan ,  Girij Pal Singh

IPC: C07D339/06 ,  C07D339/08 ,  C07D409/10 ,  C07D487/04 ,  C07D243/10 ,  A61K31/55 ,  C07D243/14

CPC classification number: C07D409/10 ,  C07D339/06 ,  C07D339/08 ,  C07D487/04

Abstract: A multistep process for producing 8-chloro-6-(2-fluorophenyl)-1-methyl-4-H-imidazo�1,5a!�1,4! benzodiazepine (midazolam) comprises treating a compound of Formula II with a lower alkyl dithiol to produce a compound of Formula III, wherein n=2 or 3, converting the compound of Formula III to a compound of Formula VII, and then treating the compound of Formula VII with a deprotecting agent, thereby producing midazolam. Novel intermediate compounds are also disclosed.

Abstract translation: 用于制备8-氯-6-（2-氟苯基）-1-甲基-4H-咪唑并[1,5a] [1,4]苯并二氮杂（咪达唑仑）的多步方法包括用较低的 制备式III化合物，其中n = 2或3，将式III化合物转化为式VII化合物，然后用脱保护剂处理式VII化合物，从而产生咪达唑仑。 还公开了新的中间体化合物。

公开(公告)号：US4343751A

公开(公告)日：1982-08-10

申请号：US186836

申请日：1980-09-15

Applicant: Naresh Kumar

Inventor： Naresh Kumar

IPC: A01K1/015 ,  B01J2/12 ,  B28B1/00 ,  C01B33/26 ,  C05G3/00 ,  C09K17/04

CPC classification number: C09K17/04 ,  A01K1/0152 ,  A01K1/0154 ,  B01J2/12 ,  B28B1/004 ,  C01B33/26 ,  C05G3/0017 ,  Y02P40/63

Abstract: An agglomeration process in which clay fines alone or in combination with other materials are agglomerated to a usable pellet size for a variety of marketable end products. The clay fines are collected, prepared and blended with conditioners and/or other waste materials in the proportions necessary to produce the desired pellet characteristics. The blended materials are preweighed and measured, permitting batch feeding to the agglomerator. The agglomerated pellets are dried and screened, with the oversize pellets being passed through a granulator to reduce their size and then being rescreened, and the undersized pellets being recycled to the collecting step for reagglomeration. Hence, the process provides pellets of relatively uniform size with little or no waste from the agglomeration procedure. The pellets may be impregnated or coated with a variety of substances, including fertilizers, pesticides, odor reducing substances, and colorants to provide a variety of different end products, including cat box filler, fertilizers, soil conditioners and floor absorbent.

Abstract translation: 单独或与其他材料结合使用的粘土粉末聚集成可用于各种可销售的最终产品的颗粒尺寸的附聚过程。 按照生产所需颗粒特性所需的比例收集，制备和与调节剂和/或其它废料混合的粘土细粉。 混合的材料被预称重和测量，允许批量进料到附聚器。 将聚集的颗粒干燥并筛分，其中过大的颗粒通过造粒机以减小其尺寸，然后被重新筛选，并且将过小的颗粒再循环到收集步骤以进行再聚集。 因此，该方法提供具有相对均匀尺寸的颗粒，很少或没有来自附聚过程的废物。 颗粒可以浸渍或涂覆各种物质，包括肥料，杀虫剂，除臭物质和着色剂，以提供各种不同的最终产品，包括猫盒填充剂，肥料，土壤调理剂和地板吸收剂。

公开(公告)号：US09586928B2

公开(公告)日：2017-03-07

申请号：US14118116

申请日：2012-05-16

Applicant: Theodore Mark Kamenecka ,  Patrick R. Griffin ,  Youseung Shin ,  Yuanjun He ,  Anne-Laure Blayo ,  Brent R. Lyda ,  Marcel Koenig ,  Naresh Kumar ,  Thomas Burris

Inventor： Theodore Mark Kamenecka ,  Patrick R. Griffin ,  Youseung Shin ,  Yuanjun He ,  Anne-Laure Blayo ,  Brent R. Lyda ,  Marcel Koenig ,  Naresh Kumar ,  Thomas Burris

IPC: C07D213/74 ,  C07D213/36 ,  C07D295/096 ,  C07D295/185 ,  C07D295/195 ,  C07D295/26 ,  C07D277/64 ,  C07D207/09 ,  C07D211/22 ,  C07D233/61 ,  C07D317/50 ,  C07D213/82 ,  C07D215/12 ,  C07D317/58 ,  C07D319/20 ,  C07D333/20 ,  C07D333/34 ,  C07D401/12 ,  C07D277/28 ,  C07D209/14 ,  C07D295/205 ,  C07D295/215 ,  C07D213/61 ,  C07D213/64 ,  C07D307/24 ,  A61K31/495 ,  A61K31/496 ,  A61K31/5375 ,  A61K31/5377 ,  A61K45/06

CPC classification number: C07D317/50 ,  A61K31/495 ,  A61K31/496 ,  A61K31/5375 ,  A61K31/5377 ,  A61K45/06 ,  C07D207/09 ,  C07D209/14 ,  C07D211/22 ,  C07D213/36 ,  C07D213/61 ,  C07D213/64 ,  C07D213/74 ,  C07D213/82 ,  C07D215/12 ,  C07D233/61 ,  C07D277/28 ,  C07D277/64 ,  C07D295/096 ,  C07D295/185 ,  C07D295/205 ,  C07D295/215 ,  C07D295/26 ,  C07D307/24 ,  C07D317/58 ,  C07D319/20 ,  C07D333/20 ,  C07D333/34 ,  C07D401/12

Abstract: The invention provides small molecule modulators of retinoic acid receptor-related orphan receptors such as RORα, RORβ, or RORγ, of formula with the variable atoms as defined herein and R1 comprising a hydroxyl- or alkoxyl-substituted fluoroalkyl group. Compounds of the invention can be effective modulators at concentrations ineffective to act on LXR receptors, or on other nuclear receptors, or other biological targets. Methods of modulation the RORs and methods of treating metabolic disorders, immune disorders, cancer, and CNS disorders wherein modulation of an ROR is medically indicated are also provided.

Abstract translation: 本发明提供了视黄酸受体相关的孤儿受体如RORα，ROR和bgr或RORγ的小分子调节剂。 本发明的化合物可以是无效作用于LXR受体或其它核受体或其他生物靶标的有效调节剂。 还提供调节ROR的方法和治疗代谢紊乱，免疫疾病，癌症和中枢神经系统疾病的方法，其中医学指示ROR的调节。

公开(公告)号：US08220033B2

公开(公告)日：2012-07-10

申请号：US11418051

申请日：2006-05-03

Applicant: Raymond K. Ng ,  Ganesh Kirti ,  Thomas Keefe ,  Naresh Kumar

Inventor： Raymond K. Ng ,  Ganesh Kirti ,  Thomas Keefe ,  Naresh Kumar

IPC: H04L29/06

CPC classification number: H04L63/062

Abstract: One embodiment of the present invention provides a system that facilitates accessing a credential. During operation, the system receives a request at a credentials-storage framework (CSF) to retrieve the credential. If a target credential store containing the credential is not already connected to the CSF, the system looks up a bootstrap credential for the target credential store in a bootstrap credential store, which contains bootstrap credentials for other credential stores. Next, the system uses this bootstrap credential to connect the CSF to the target credential store. Finally, the system retrieves the credential from the target credential store, and returns the credential to the requestor.

Abstract translation: 本发明的一个实施例提供一种便于访问证书的系统。 在操作期间，系统在凭证存储框架（CSF）处接收请求以检索凭证。 如果包含凭据的目标凭据存储库尚未连接到CSF，则系统将在引导凭证存储中查找目标凭据存储的引导凭据，其中包含其他凭据存储的引导凭据。 接下来，系统使用此引导凭据将CSF连接到目标凭据存储。 最后，系统从目标凭证存储中检索凭证，并将凭证返回给请求者。